search
Back to results

Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening

Primary Purpose

Hip Arthrosis

Status
Completed
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Clodronate
Saline
Sponsored by
University of Oulu
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Arthrosis focused on measuring RSA, DXA, Bisphosphonates, Migration of stem, Aseptic loosening of prosthesis

Eligibility Criteria

undefined - 73 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • hip arthrosis and
  • a primary THA was planned

Exclusion Criteria:

  • renal insufficiency
  • hypercalcemia
  • malignant tumors
  • contemporaneously treatment with another bisphosphonate or aminoglycoside

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Clodronate

    Saline

    Arm Description

    1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.

    1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.

    Outcomes

    Primary Outcome Measures

    Maximal total point motion (MTPM) - migration of the femoral stem
    It represents the length of the translation vector of the point in a rigid body that has the greatest motion. It can only have positive values, and is not normally distributed. The reason for using MTPM is that in many cases, motion implies a biological effect of some kind and this effect is liable to be greatest at the point of maximum motion. The parameter has been measured by RSA-methods, which is an accurate method of determining the migration and wear of orthopaedic implants: it determine the precise location of two distinct objects relative to each other in three dimension such as the relative position of the femoral component and the proximal femur. In radiostereometric analysis the position in space of the original object is reconstructed from a two dimensional x-ray film using tantalum beads. Movement between segments is then calculated by localizing each segment in a coordinate system. Lower values represent a better outcome.

    Secondary Outcome Measures

    Bone mineral density (BMD) in 7 Gruen zones
    BMD was measured by dual-energy X-ray absorptiometry, DXA. In clinical use, precision errors are < 5 %. To evaluate the horizontal linear distribution of the BMD, seven Gruen zones, peri-prosthetic sub-regions of interest, ROI (region of interest) were calculated by the software on the anteroposterior view of the proximal femur. The value of BMD is g/cm2 and it estimates the strength of the bone. Higher values/lesser decrease in values represent a better outcome.

    Full Information

    First Posted
    January 4, 2019
    Last Updated
    January 16, 2019
    Sponsor
    University of Oulu
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03803839
    Brief Title
    Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening
    Official Title
    Could the Intra-operative Clodronate Rinsing Improve the Integration of the Femoral Stem in a Prospective, Double-blinded, Randomized, Placebo-controlled Clinical RSA-study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    March 26, 2004 (Actual)
    Primary Completion Date
    March 12, 2014 (Actual)
    Study Completion Date
    March 12, 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Oulu

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Periprosthetic bone-loss after total hip arthroplasty (THA), detected as an early migration of the prosthesis, may predict later loosening. The investigators hypothesized that by reducing bone resorption after THA with bisphosphonates, it might be possible to achieve better early fixation of the implant. Nineteen patients suffering arthrosis were recruited to a prospective, double-blinded, randomized, placebo-controlled clinical pilot trial. Patients were operated with an uncemented Bimetric stem with tantalum markers, the acetabular cup and liner were chosen by the surgeon. The femoral proximal intramedullary canal was rinsed with 1mM (millimole) clodronate, that was done by adding the clodronate to the 1000 ml 0.9% NaCl (sodium chloride) in nine patients and rinsing solution was the pure 0.9% NaCl for 10 patients. These rinsing packages were labeled only with the code from the pharmacy of the hospital. These patients were followed for two years using radiostereometric analysis (RSA), dual energy x-ray absorptiometry (DXA) and the Harris hip score (HHS). The purpose of the investigator's study was to examine whether the local intraoperative administration of clodronate could reduce periprosthetic bone loss and further stem migration after primary THA.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hip Arthrosis
    Keywords
    RSA, DXA, Bisphosphonates, Migration of stem, Aseptic loosening of prosthesis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Parallel Assignment
    Model Description
    In this prospective, double-blinded, randomized, placebo-controlled clinical trial with two years follow-up period the investigators rinsed the proximal intramedullary cavity of the femur with either clodronate (60 mg clodronate in 1000 ml saline) or saline (1000 ml saline) prior to the application of the femoral stem.
    Masking
    ParticipantCare ProviderInvestigator
    Masking Description
    Patients were randomized into two treatment groups; either the clodronate or a placebo group. All patients, surgeons and other personnel in the operating theatre were blinded as to the patients' study group.
    Allocation
    Randomized
    Enrollment
    19 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Clodronate
    Arm Type
    Active Comparator
    Arm Description
    1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
    Arm Title
    Saline
    Arm Type
    Placebo Comparator
    Arm Description
    1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
    Intervention Type
    Drug
    Intervention Name(s)
    Clodronate
    Intervention Type
    Drug
    Intervention Name(s)
    Saline
    Primary Outcome Measure Information:
    Title
    Maximal total point motion (MTPM) - migration of the femoral stem
    Description
    It represents the length of the translation vector of the point in a rigid body that has the greatest motion. It can only have positive values, and is not normally distributed. The reason for using MTPM is that in many cases, motion implies a biological effect of some kind and this effect is liable to be greatest at the point of maximum motion. The parameter has been measured by RSA-methods, which is an accurate method of determining the migration and wear of orthopaedic implants: it determine the precise location of two distinct objects relative to each other in three dimension such as the relative position of the femoral component and the proximal femur. In radiostereometric analysis the position in space of the original object is reconstructed from a two dimensional x-ray film using tantalum beads. Movement between segments is then calculated by localizing each segment in a coordinate system. Lower values represent a better outcome.
    Time Frame
    0 to 24 months
    Secondary Outcome Measure Information:
    Title
    Bone mineral density (BMD) in 7 Gruen zones
    Description
    BMD was measured by dual-energy X-ray absorptiometry, DXA. In clinical use, precision errors are < 5 %. To evaluate the horizontal linear distribution of the BMD, seven Gruen zones, peri-prosthetic sub-regions of interest, ROI (region of interest) were calculated by the software on the anteroposterior view of the proximal femur. The value of BMD is g/cm2 and it estimates the strength of the bone. Higher values/lesser decrease in values represent a better outcome.
    Time Frame
    0 to 24 months
    Other Pre-specified Outcome Measures:
    Title
    Migration of femoral stem
    Description
    Subsidence and vertical movement of the femoral stem (scale micrometers), x-, y- and z-translations. Parameters were measured using RSA-methods and the scaling is linear. Lower values represent a better outcome.
    Time Frame
    0 to 24 months
    Title
    The maximal (MTPM) maximal total point motion
    Description
    The maximal MTPM value after 3 months when the expected integration of stem should have happened. Lower values represent a better outcome.
    Time Frame
    3 to 24 months
    Title
    Correlation between baseline BMD and the maximal MTPM
    Description
    This parameters summarize the BMD and RSA values together. The investigators have planned it to evaluate the correlation between the quality of periprosthetic bone in baseline and the migration of femoral stem during 2 years follow-up period between the study groups.
    Time Frame
    BMD (0 month) - the maximal MTPM 3 to 24 months
    Title
    Harris Hip Score (HHS)
    Description
    Harris Hip Score (HHS) is a clinician-based outcome measure, health status scale, that is frequently used to measure the outcome of total hip arthroplasty. It is measured by questionnaire that give points from 0 to 100. Higher values represent a better outcome.
    Time Frame
    0 to 24 months

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    73 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: hip arthrosis and a primary THA was planned Exclusion Criteria: renal insufficiency hypercalcemia malignant tumors contemporaneously treatment with another bisphosphonate or aminoglycoside

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    De-identified individual participant data for all primary and secondary outcome data will be made available.
    IPD Sharing Time Frame
    Data will be available after submitting the results to the scientific journals and five years after the publication.
    IPD Sharing Access Criteria
    Data Access requests will be reviewed By an external Independent Review Panel. Requestors will be required to sign a Data Access Agreement.

    Learn more about this trial

    Locally Administered Clodronate in the Prevention of Aseptic Implant Loosening

    We'll reach out to this number within 24 hrs